Log In
BCIQ
Print this Print this
 

XOMA 089

  Manage Alerts
Collapse Summary General Information
Company Xoma Corp.
Description mAb targeting transforming growth factor (TGF) beta 1 (TGFB1) and TGFB2
Molecular Target Transforming growth factor (TGF) beta 1 (TGFB1) ; Transforming growth factor (TGF) beta 2 (TGFB2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$517.0M

$37.0M

$480.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/01/2015

$517.0M

$37.0M

$480.0M

Get a free BioCentury trial today